Workflow
银诺医药-B(02591.HK)预计8月15日上市 引入迈富时等基石
Ge Long Hui·2025-08-06 22:52

Group 1 - The company, Silver诺医药-B (02591.HK), plans to globally offer 36.5564 million H-shares, with 3.6558 million shares available in Hong Kong and 32.9006 million shares for international offering, with a proposed price of HKD 18.68 per share [1] - The subscription period for the shares is set from August 7 to August 12, 2025, with trading expected to commence on August 15, 2025 [1] - The company has developed a pipeline of candidate drugs targeting diabetes and other metabolic diseases since its establishment in 2014, including the core product, Isupatide α, which has received regulatory approval for treating type 2 diabetes in China [1] Group 2 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares totaling USD 10 million (approximately HKD 78.5 million) at the offering price [2] - Assuming no exercise of the over-allotment option and a share price of HKD 18.68, the net proceeds from the global offering are expected to be approximately HKD 610.1 million [2] - The company plans to allocate approximately 90% of the net proceeds to ongoing and planned clinical trials and commercialization of Isupatide α, with 62.4% for further clinical research and 27.6% for commercialization efforts [2]